RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now These new developments, along with the reality that Big Pharma is facing a looming patent cliff by 2025, are reasons why the competition for innovative biopharmaceuticals companies that are involved in the treatment of cancer is significant, and why a proposed acquisition price for ONCY's multi-functional Platform Technology can be correctly seen as north of US$8 Billion.